Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #50237 on Medizone Intl. (fka MZEIQ)
ResidentAmerican
02/12/20 9:37 AM
#50238 RE: Tane61 #50237
Tane61
02/12/20 10:06 AM
#50239 RE: Tane61 #50237
03/07/20 2:38 AM
#50268 RE: Tane61 #50237
In 1990, the Canadian Blood Forces Program (under the aegis of the Canadian Department of Defense and Agriculture and the Canadian Red Cross) requested that the Company add the Medizone Technology to the other proprietary technology being investigated as an experimental arm of an ozone- based blood sterilization investigative program. The program was an attempt to develop an effective technology for sterilizing whole blood and blood products. This program, which was to study the Medizone Technology as it relates to the inactivation of Simian Immunodeficiency Virus ("SIV"), included a live primate model. The program continued until 1994, completing two out of the three proposed stages, when the funding arm of the Canadian Blood Forces Program discontinued funding the program. The Company's current management learned in late 1997 that the program, as it involves the Medizone Technology, was stopped primarily due to an equipment failure and the generation of erroneous data due to the equipment failure. The third stage of the study was resumed in May 1996, but did not utilize the Medizone Technology.